Claims for Patent: 10,815,455

Summary for Patent: 10,815,455

Title:	Salmonella-based vectors for cancer immunotherapy targeting Wilms\' tumor gene WT1
Abstract:	The present invention relates to an attenuated mutant strain of Salmonella comprising a recombinant DNA molecule encoding Wilms\' tumor Protein I. In particular, the present invention relates to the use of said attenuated mutant strain of Salmonella in cancer immunotherapy.
Inventor(s):	Lubenau; Heinz (Neustadt an der Weinstrasse, DE), Springer; Marco (Wendlingen, DE)
Assignee:	Vaximm AG (CH)
Application Number:	15/872,750
Patent Claims:	1. A method of treating a Wilms' Tumor Protein (WT1) expressing cancer, comprising administering orally to a subject a DNA vaccine comprising an attenuated mutant strain of Salmonella enterica typhi Ty21a comprising at least one copy of a recombinant DNA molecule comprising a eukaryotic expression cassette encoding WT1 in cancer immunotherapy, wherein the vaccine is not HLA-restricted. 2. The method of claim 1, wherein WT1 is human WT1. 3. The method of claim 1, wherein the recombinant DNA molecule comprises a kanamycin antibiotic resistance gene, a pMB1 ori, and a eukaryotic expression cassette encoding human WT1 under the control of a CMV promoter. 4. The method of claim 1, wherein the cancer immunotherapy further comprises administration of one or more further attenuated mutant strain(s) of Salmonella comprising at least one copy of a recombinant DNA molecule comprising an expression cassette encoding a tumor antigen and/or a tumor stroma antigen. 5. The method of claim 4, wherein the attenuated mutant strain of Salmonella is co-administered with said one or more further attenuated mutant strain(s) of Salmonella. 6. The method of claim 1, wherein cancer immunotherapy is accompanied by chemotherapy, radiotherapy or biological cancer therapy. 7. The method of claim 1, wherein the cancer is selected from leukemia and solid tumors. 8. The method of claim 1, wherein the attenuated mutant strain of Salmonella is administered as the single dose comprising from about 10.sup.5 to about 10.sup.11 colony forming units (CFU). 9. The method of claim 1, for individualized cancer immunotherapy comprising a step of assessing a tumor antigen expression pattern and/or stroma antigen expression pattern of the subject. 10. The method of claim 1, wherein WT1 is truncated and the truncated WT1 has the amino acid sequence as found in SEQ ID NO 1. 11. The method of claim 4, wherein said one or more further attenuated mutant strain(s) of Salmonella is/are Salmonella typhi Ty21a comprising a eukaryotic expression cassette. 12. The method of claim 11, wherein said one or more further attenuated mutant strain(s) of Salmonella comprise(s) an attenuated mutant strain of Salmonella encoding human VEGFR-2. 13. The method of claim 7, wherein the leukemia is selected from acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL). 14. The method of claim 7, wherein the solid tumor is selected from lung cancer, breast cancer, esophageal, colon, colorectal, gastric, cholangioductal, pancreatic cancer, glioblastoma, head and neck cancer, synovial sarcoma, angiosarcoma, osteosarcoma, thyroid cancer, cervical, endometrial, ovarian cancer, neuroblastoma, rhabdomyosarcoma and prostate cancer.

Details for Patent 10,815,455

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bavarian Nordic A/s	VIVOTIF	typhoid vaccine live oral ty21a	Capsule	103123	December 15, 1989	10,815,455	2038-01-16